Hansoh Pharmaceutical Group Company Limited
翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

VOLUNTARY ANNOUNCEMENT

B7-H3-TARGETED ANTIBODY-DRUG CONJUGATE HS-20093 RECEIVED FDA BREAKTHROUGH THERAPY DESIGNATION IN LATE-LINE RELAPSED OR REFRACTORY OSTEOSARCOMA

Reference is made to the announcement of Hansoh Pharmaceutical Group Company Limited (the "**Company**" and together with its subsidiaries, the "**Group**") dated December 20, 2023 in relation to the entry of a license agreement between the Group and GlaxoSmithKline Intellectual Property (No. 4) Limited ("**GSK**"), pursuant to which GSK obtained an exclusive worldwide license (excluding the Chinese Mainland, Hong Kong, Macau, and Taiwan) to develop, manufacture and commercialize HS-20093.

The board of directors (the "**Board**") of the Company is pleased to announce that GSK has received the U.S. Food and Drug Administration ("**FDA**") Breakthrough Therapy Designation ("**BTD**") for GSK5764227 (GSK'227, also known as HS-20093), the B7-H3-targeted antibody-drug conjugate ("**ADC**") being evaluated for the treatment of adult patients with relapsed or refractory osteosarcoma (bone cancer) who have progressed on at least two prior lines of therapy.

ABOUT HS-20093

HS-20093 is a novel investigational B7-H3-targeted ADC composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to topoisomerase inhibitor (TOPOi) payload and being developed for the treatment of lung cancer, sarcoma, head and neck cancers and other solid tumors in multiple phase I, II and III clinical trials in China.

On August 20, 2024, GSK announced that the FDA granted BTD for GSK'227 for extensive-stage small-cell lung cancer ("**ES-SCLC**") patients with disease progression on or after platinum-based chemotherapy (relapsed or refractory). On November 1, 2024, the National Medical Products Administration of China listed HS-20093 as a Breakthrough-Therapy-Designated Drug, with the proposed indication being ES-SCLC developed after standard first-line treatment (platinum doublet chemotherapy combined with immuno-therapy). On December 16, 2024, GSK announced that European Medicines Agency (EMA) granted Priority Medicines (PRIME) Designation for GSK'227 for the treatment of patients with relapsed ES-SCLC.

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, January 7, 2025

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Ms. Sun Yuan and Dr. Lyu Aifeng as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.